Research

Energy balance

Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.

A minority of patients may maintain long-term use of GLP-1 RAs, indicating potential for sustained treatment benefits.

StrongSupportsmedium confidence
Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.
Dehshini Ali et al. · Diabetes Obesity and Cardiometabolic CARE · 2026

Why this rating

Based on a retrospective cohort study design.

Source

Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity

Dehshini Ali et al. · Diabetes Obesity and Cardiometabolic CARE · 2026

DOI 10.2337/doc25-0026

cohort · n=9189
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →